05:50 AM EDT, 08/06/2026 (MT Newswires) -- Solvonis Therapeutics (SVNS.L) said Thursday its proprietary discovery-stage small molecule, SVN-015, will advance to further evaluation under the US National Institute on Drug Abuse's Addiction Treatment Discovery Program. The update follows the completion of the initial cardiac ion-channel screening, in which the compound demonstrated an encouragingly broad off-target profile. SVN-015 is being assessed as a potential treatment for stimulant use disorder, including cocaine and methamphetamine use disorders. The clinical-stage biopharmaceutical company's drug will now progress to further studies aimed at characterizing its intended transporter pharmacology, off-target profile, and in vivo activity.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.